Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, NY 10021, USA.
Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C1, Canada.
Future Oncol. 2021 Aug;17(22):2923-2939. doi: 10.2217/fon-2021-0284. Epub 2021 Apr 15.
Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.
比较索拉菲尼与安慰剂在去分化脂肪肉瘤患者中的健康相关生活质量（HRQoL）。使用欧洲癌症研究与治疗组织的 30 项核心生活质量问卷，在基线和每个周期的第 1 天评估 HRQoL。结果从基线报告至第 169 天（在此期间，在保持足够样本量的同时，最大限度地延长治疗暴露时间）。在所有随访中，安慰剂组的疼痛评分均较基线恶化，而索拉菲尼组的疼痛评分则恶化，尽管在某些随访中差异无统计学意义。其他领域在手臂之间没有表现出显著差异；然而，随着时间的推移，两个手臂的分数都有所下降。与接受安慰剂治疗的患者相比，接受索拉菲尼治疗的患者报告的疼痛发生率较低，且疼痛恶化速度较慢。
